Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06126276 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 243 record versions are listed below. See every version on ClinicalTrials.gov ↗

  1. Site details revised at 3 of 194 sites
  2. Site details revised at 1 of 194 sites
  3. Site details revised at 4 of 194 sites
  4. Site contacts updated at 3 of 194 sites
  5. Re-verified, no change to tracked fields
Show 45 earlier versionsHide 45 earlier versions
  1. Site details revised at 1 of 194 sites
  2. Study sites: 193 to 194
    • Eligibility criteria expanded, about 35 words
  3. Site details revised at 1 of 193 sitesv236
  4. Site details revised at 2 of 193 sitesv235
  5. Study sites: 192 to 193v234
  6. Study sites: 190 to 192v233
  7. Study sites: 189 to 190v232
  8. Site details revised at 1 of 189 sitesv231
  9. Site details revised at 1 of 189 sitesv230
  10. Site contacts updated at 1 of 189 sitesv229
  11. Site details revised at 1 of 189 sitesv228
  12. Site details revised at 3 of 189 sitesv227
  13. Site details revised at 1 of 189 sitesv226
  14. Study sites: 188 to 189v225
  15. Study sites revised (188)v224
  16. Site details revised at 3 of 188 sitesv223
  17. Site details revised at 1 of 188 sitesv222
  18. Site details revised at 2 of 188 sitesv221
  19. Site details revised at 2 of 188 sitesv220
  20. Site details revised at 3 of 188 sitesv219
  21. Site details revised at 1 of 188 sitesv218
  22. Site details revised at 2 of 188 sitesv217
  23. Study sites revised (188)v216
  24. Site details revised at 3 of 188 sitesv215
  25. Study sites: 187 to 188v214
  26. Study sites revised (187)v213
  27. Site contacts updated at 1 of 187 sitesv212
  28. Site details revised at 5 of 187 sitesv211
  29. Site details revised at 5 of 187 sitesv210
  30. Re-verified, no change to tracked fieldsv209
  31. Study sites: 186 to 187v208
  32. Study sites: 185 to 186v207
  33. Study sites revised (185)v206
  34. Study sites: 186 to 185v205
  35. Site details revised at 1 of 186 sitesv204
  36. Study sites: 185 to 186v203
  37. Site details revised at 1 of 185 sitesv202
  38. Re-verified, no change to tracked fieldsv201
  39. Site details revised at 1 of 185 sitesv200
  40. Study sites: 184 to 185v199
  41. Site details revised at 1 of 184 sitesv198
  42. Site details revised at 1 of 184 sitesv197
  43. Study sites: 182 to 184v196
  44. Site details revised at 7 of 182 sitesv195
  45. Site details revised at 7 of 182 sitesv194
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II ComboMATCH treatment trial compares the effect of neratinib to the combination of neratinib and palbociclib in treating patients with HER2 positive solid tumors. Neratinib and palbociclib are in a class of medications called kinase inhibitors. They work by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of tumor cells. Giving neratinib and palbociclib in combination may shrink or stabilize cancers that over-express a specific biomarker called HER2.
Trial Details
NCT Number NCT06126276
Lead Sponsor National Cancer Institute (NCI)
Conditions
(from sponsor)		 Malignant Female Reproductive System Neoplasm, Malignant Solid Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm
Enrollment 70 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov